

ARCA biopharma, Inc.  
Form 8-K/A  
May 09, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K/A**

(Amendment No. 1)

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): May 9, 2013 (May 2, 2013)**

**ARCA biopharma, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction)

**000-22873**  
(Commission)

**36-3855489**  
(I.R.S. Employer)

Edgar Filing: ARCA biopharma, Inc. - Form 8-K/A

of Incorporation)

File Number)

Identification No.)

**8001 Arista Place, Suite 430, Broomfield, CO 80021**

(Address of Principal Executive Offices) (Zip Code)

**(720) 940-2200**

(Registrant's Telephone Number, Including Area Code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**

As previously disclosed in a Form 8-K filed on May 6, 2013, Burton E. Sobel, a member of the board of directors of ARCA biopharma, Inc. ( ARCA ), died on May 2, 2013.

ARCA notified The NASDAQ Stock Market LLC ( NASDAQ ) on May 6, 2013 of Dr. Sobel s death. As a result of his death, ARCA no longer has at least three audit committee members, as required by NASDAQ Listing Rule 5605(c)(2)(A).

Consistent with the cure period provided in NASDAQ Listing Rule 5605(c)(4)(B), ARCA expects to cure this deficiency before the earlier of the Company s next annual stockholders meeting or May 2, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ARCA biopharma, Inc.**

(Registrant)

Date: May 9, 2013

By: /s/ Christopher D. Ozeroff  
Name: Christopher D. Ozeroff  
Title: SVP & General Counsel